Kevin Dunleavy

For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated

Haleon reels in $633M with sale of ex-US nicotine replacement unit to Dr. Reddy's

With U.K. consumer health giant Haleon slimming down and India’s Dr. Reddy’s Laboratories beefing up its over-the-counter offerings, the two have arrived at a deal that makes sense for both. | Haleon...

Sanofi, Pfizer, AstraZeneca invest a combined €1.87B to bolster operations in France

In two months, countries from around the world will send athletes to France to compete in the 2024 Summer Olympics. But this week in Paris is all about lighting the torch for big business. | Sanofi...

Roche's soaring Vabysmo sales raise the stakes in ophthalmology face-off with Regeneron's Eylea:...

Roche’s long-awaited challenge to Regeneron’s dominance in the ophthalmology market may soon be coming to a head, according to a recent analyst report from GlobalData. | Roche’s long-awaited challe...

After trial failure, will Amylyx pull ALS drug Relyvrio off the market?

After reporting the failu | After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull...

Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says

Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Vertex and CRISPR Therapeutics are up first with a Dec. | Two long-awaited treatments for...

Nothing to Seagen here: Merck remains mum on merger

Without a single word in its press release about Seagen—the powerful biotech it has reportedly been targeting for a buyout over the last several weeks—Merck revealed second-quarter earnings on Thur |...

Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen

As its stock price plummeted early this year, what did Massachusetts biotech Epizyme do to try to stop the bleeding? | As its stock price plummeted early this year, what did Massachusetts biotech...

In bankruptcy case, US wants court to block J&J's use of high-powered, highly paid lawyer Neal...

At the powerful law firm of Hogan Lovells, partner Neal Katyal is decidedly a “rainmaker.” So what does it cost to make it rain? $2,465. Per hour. | In Johnson & Johnson's bankruptcy case, in which...

Pfizer, Merck and AstraZeneca led Big Pharma's growth in Q1 but they couldn't match mRNA hotshots

Seagen CEO's arrest came during a hazy night of booze, sex and alleged violence: police report

A police report of the domestic abuse arrest of Seagen CEO Clay Siegall, Ph.D., describes a drunken night involving him, his wife and another couple and includes sexual escapades and alleged violen |...